Regulatory Update: Not Yet Recruiting Hormonal Regulation Study in Cardiometabolic Health Targets Surgically Menopausal Population

What changed?

The ClinicalTrials.gov entry identifies a condition focused on menopause that results from surgical intervention and records two primary intervention types: the surgical removal of ovaries and hormone replacement therapy. The not yet recruiting status signals that participant enrolment has not begun and that investigators are in the planning and regulatory alignment stage. The record also lists a broad consortium of sponsors spread across universities and health districts in Finland, illustrating a multi기관 collaboration approach typical of large scale hormonal regulation studies.

What is the trial status and scope?

The study is described as not yet recruiting and is catalogued with a surgical health context. The scope includes a population affected by surgical menopause and the interventions of oophorectomy and hormone replacement therapy. The sponsor network includes the University of Jyvaskyla and several Wellbeing Services across Finnish regions along with the Hospital District of Helsinki and Uusimaa. While the record does not provide enrolment timelines, it does indicate a structured international style sponsor framework and a formal trial registry presence to support regulatory transparency for future phases.

What this means for regulators is that the project remains in early planning and documentation stages. Regulators will expect subsequent updates as enrolment begins, as well as clear reporting of safety signals and study outcomes once data become available. The inclusion of both a surgical procedure and a pharmacologic therapy in the same trial underscores the need for careful regulatory coordination across medical device and pharmaceutical domains if devices or delivery systems enter the protocol in later stages. Access to the official registry page is available here: ClinicalTrials.gov record.

What are the regulatory implications for health systems and sponsors?

From a regulatory affairs perspective this entry demonstrates ongoing compliance with trial registry requirements and a commitment to upfront public disclosure of trial purpose, interventions and sponsor structure. No device specific claims are documented in the current record, which instead centers on a surgical and pharmacologic approach to hormonal regulation. If future amendments include a device component or a device based delivery mechanism, sponsors should anticipate MDR Annex XIV style disclosures and device level performance and safety data. In practice this means a clear intended use statement, defined performance metrics, and robust safety reporting aligned with regulatory expectations for medical devices, while maintaining separate requirements for pharmacological and surgical components where applicable.

For readers assessing risk and compliance, the Finnish multi sponsor framework may require cross agency communication and harmonization across institutions. The trial record serves as a baseline posture for regulatory readiness, including participant protections, data integrity, and transparent reporting practices. The page also points readers to the external registry for authoritative details: ClinicalTrials.gov.

Who sponsors the study and what is the funding network?

The listed sponsors reflect a broad collaboration among academic and regional health authorities in Finland. The University of Jyvaskyla appears prominently alongside multiple Wellbeing Services County organizations and the Hospital District of Helsinki and Uusimaa. This diversified sponsor model supports cross regional research capabilities, enabling a more comprehensive approach to studying hormonal regulation in a surgical menopausal population. The arrangement suggests a plan for shared governance, data stewardship, and potential future expansion to additional centers if enrolment progresses.

Regulators and stakeholders should monitor the evolving sponsor disclosures for changes in governance and funding flow, which may influence trial oversight and site qualifications. The registry note confirms the not yet recruiting status and the structure of the sponsor network, while the external record provides an official reference point for ongoing updates.

FAQ

1. 1. What is the focus of this trial?
   It examines hormonal regulation of cardiometabolic health in women who have undergone surgical menopause, using both a surgical procedure and hormone replacement therapy as interventions.
2. 2. What is the enrolment status?
   The record indicates not yet recruiting, meaning no participants have been enrolled at this time.
3. 3. Who sponsors the study?
   A network of institutions includes the University of Jyvaskyla and multiple Finnish health service counties as well as the Hospital District of Helsinki and Uusimaa.
4. 4. Where is the trial registered?
   The trial is listed on ClinicalTrials.gov with the identifier NCT07406412.
5. 5. How can I access more information?
   Visit the ClinicalTrials.gov record via the external link provided in this article for the official, up to date registry entry.

Conclusion

This not yet recruiting trial highlights ongoing regulatory transparency around a multi center study of hormonal regulation in surgically menopausal women. Regulators and health system partners should watch for enrolment updates, safety reporting, and results dissemination as the study moves toward activation. The collaboration across universities and regional health authorities signals a coordinated approach that may influence future regulatory expectations for similar trials involving hormonal therapies and surgical interventions.

Disclaimer

This summary is intended for professionals and is not legal advice. It should not be construed as clinical guidance. Readers should consult the official registry and regulatory documents for precise requirements and updates.

Announcement line

For full information about the announcement, see the link below.

https://clinicaltrials.gov/study/NCT07406412?term=medical+device